-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
-
Summary
-
Adaptimmune Therapeutics PLC quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from Q1 2017 to Q1 2024.
- Adaptimmune Therapeutics PLC Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2024 was $29.2M, a 14816% increase year-over-year.
- Adaptimmune Therapeutics PLC annual Net Cash Provided by (Used in) Financing Activities for 2023 was $880K, a 93.2% decline from 2022.
- Adaptimmune Therapeutics PLC annual Net Cash Provided by (Used in) Financing Activities for 2022 was $12.9M, a 291% increase from 2021.
- Adaptimmune Therapeutics PLC annual Net Cash Provided by (Used in) Financing Activities for 2021 was $3.29M, a 99% decline from 2020.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)